Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD73: A potential biomarker for anti-PD-1 therapy.

Literature DB >> 26451321

CD73: A potential biomarker for anti-PD-1 therapy.

Paul A Beavis¹, Clare Y Slaney¹, Nicole Milenkovski¹, Melissa A Henderson¹, Sherene Loi¹, John Stagg², Michael H Kershaw³, Phillip K Darcy³.

Abstract

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson's Disease, this combination warrants further investigation.

Entities: Disease Gene Species

Keywords: CD73; adenosine; anti-PD-1; cancer; immunotherapy

Year: 2015 PMID： 26451321 PMCID： PMC4589050 DOI： 10.1080/2162402X.2015.1046675

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Authors: Deepak Mittal; Arabella Young; Kimberley Stannard; Michelle Yong; Michele W L Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal: Cancer Res Date: 2014-07-01 Impact factor: 12.701

2. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.

Authors: Caglar Cekic; Joel Linden
Journal: Cancer Res Date: 2014-10-23 Impact factor: 12.701

3. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors: Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal: Clin Cancer Res Date: 2014-04-08 Impact factor: 12.531

4. Immunological mechanisms of the antitumor effects of supplemental oxygenation.

Authors: Stephen M Hatfield; Jorgen Kjaergaard; Dmitriy Lukashev; Taylor H Schreiber; Bryan Belikoff; Robert Abbott; Shalini Sethumadhavan; Phaethon Philbrook; Kami Ko; Ryan Cannici; Molly Thayer; Scott Rodig; Jeffrey L Kutok; Edwin K Jackson; Barry Karger; Eckhard R Podack; Akio Ohta; Michail V Sitkovsky
Journal: Sci Transl Med Date: 2015-03-04 Impact factor: 17.956

5. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Authors: Paul A Beavis; Nicole Milenkovski; Melissa A Henderson; Liza B John; Bertrand Allard; Sherene Loi; Michael H Kershaw; John Stagg; Phillip K Darcy
Journal: Cancer Immunol Res Date: 2015-02-11 Impact factor: 11.151

6. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors: Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205

7. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors: Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal: Proc Natl Acad Sci U S A Date: 2013-06-17 Impact factor: 11.205

8. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Authors: Paul A Beavis; Upulie Divisekera; Christophe Paget; Melvyn T Chow; Liza B John; Christel Devaud; Karen Dwyer; John Stagg; Mark J Smyth; Phillip K Darcy
Journal: Proc Natl Acad Sci U S A Date: 2013-08-20 Impact factor: 11.205

9. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

Authors: Raffaella Iannone; Lucio Miele; Piera Maiolino; Aldo Pinto; Silvana Morello
Journal: Am J Cancer Res Date: 2014-03-01 Impact factor: 6.166

Review 10. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Authors: Robert D Leone; Ying-Chun Lo; Jonathan D Powell
Journal: Comput Struct Biotechnol J Date: 2015-04-08 Impact factor: 7.271

10 in total

13 in total

Review 1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors: Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal: Cell Date: 2017-02-09 Impact factor: 41.582

2. Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients.

Authors: Kohei Ono; Eisuke Shiozawa; Nobuyuki Ohike; Tomonori Fujii; Hideki Shibata; Tetsuya Kitajima; Koichiro Fujimasa; Naoko Okamoto; Yukiko Kawaguchi; Tasuku Nagumo; Sakiko Tazawa; Mayumi Homma; Toshiko Yamochi-Onizuka; Tomoko Norose; Hitoshi Yoshida; Masahiko Murakami; Gensyu Tate; Masafumi Takimoto
Journal: Oncol Lett Date: 2017-12-08 Impact factor: 2.967

Review 3. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors: Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2016-03-10 Impact factor: 8.110

4. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Authors: Paul A Beavis; Melissa A Henderson; Lauren Giuffrida; Jane K Mills; Kevin Sek; Ryan S Cross; Alexander J Davenport; Liza B John; Sherly Mardiana; Clare Y Slaney; Ricky W Johnstone; Joseph A Trapani; John Stagg; Sherene Loi; Lev Kats; David Gyorki; Michael H Kershaw; Phillip K Darcy
Journal: J Clin Invest Date: 2017-02-06 Impact factor: 14.808

Review 5. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.

Authors: Siwen Hu-Lieskovan; Antoni Ribas
Journal: Cancer J Date: 2017 Jan/Feb Impact factor: 3.360